<DOC>
	<DOCNO>NCT00053339</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody trastuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Estrogen stimulate growth breast cancer cell . Hormone therapy use tamoxifen may fight breast cancer block uptake estrogen . Combining trastuzumab tamoxifen may kill tumor cell . PURPOSE : Randomized phase III trial compare effectiveness trastuzumab without trastuzumab treat woman invasive stage IV breast cancer .</brief_summary>
	<brief_title>Trastuzumab With Without Tamoxifen Treating Women With Progressive Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare time progression woman progressive , stage IV , estrogen progesterone receptor- HER2/neu-positive breast cancer treat trastuzumab ( Herceptin ) without tamoxifen . - Correlate response type measurement ( immunohistochemistry fluorescent situ hybridization ) HER2/neu expression patient treat regimen . - Compare objective response rate ( complete partial response ) patient treat regimen . OUTLINE : This randomize study . Patients stratify accord prior adjuvant treatment ( yes v ) , ECOG performance status ( 0-1 v 2 ) , prior aromatase inhibitor treatment ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive trastuzumab ( Herceptin ) IV 60-90 minute day 1 . - Arm II : Patients receive trastuzumab arm I oral tamoxifen daily day 1-21 . In arm , treatment repeat every 3 week least 2 course absence disease progression unacceptable toxicity . Patients follow every 3 month 5 year . PROJECTED ACCRUAL : A total 280 patient ( 140 per treatment arm ) accrue study within 28 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive stage IV breast cancer Hormone receptor status : HER2/neu positive ( 3+ immunohistochemical [ IHC ] assay fluorescent situ hybridization [ FISH ] ) Estrogen receptor progesterone receptor positive Measurable evaluable disease Must disease progression within 6 month initiation tamoxifen ( administer adjuvant metastatic setting ) aromatase inhibitor therapy PATIENT CHARACTERISTICS : Age 18 Sex Female Performance status ECOG 02 Hematopoietic Absolute neutrophil count least 1,000/mm^3 Platelet count least 75,000/mm^3 Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT SGPT great 2.5 time ULN Cardiovascular LVEF normal MUGA Other Not pregnant nursing Fertile patient must use effective nonhormonal contraception least 2 month study completion No concurrent active malignancy except nonmelanoma skin cancer Patients complete prior therapy le 30 % risk relapse consider active malignancy PRIOR CONCURRENT THERAPY : Biologic therapy No prior trastuzumab ( Herceptin ) adjuvant metastatic setting Chemotherapy No 1 prior chemotherapy regimen metastatic set No concurrent chemotherapy Endocrine therapy See Disease Characteristics No 1 prior hormonal therapy regimen metastatic disease Prior aromatase inhibitor therapy administer firstline metastatic adjuvant setting allow provided disease progression tamoxifen No concurrent hormonal therapy except follow : Steroids adrenal failure Hormones nondiseaserelated condition ( e.g. , insulin diabetes ) Intermittent use dexamethasone antiemetic Vaginal estrogen ( EstringÂ® ) vaginal dryness Radiotherapy No concurrent palliative radiotherapy except whole brain irradiation CNS disease Other Concurrent bisphosphonates allow No concurrent cardioprotective drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>